Background: Homozygous inactivating mutations of the calcium-sensing receptor (CaSR) lead to neonatal severe hyperparathyroidism (NSHPT), whereas heterozygous inactivating mutations result in familial hypocalciuric hypercalcemia (FHH). It is unknown why in some cases heterozygous CaSR mutations cause neonatal hyperparathyroidism (NHPT) clinically similar to NSHPT but with only moderately elevated serum calcium. Methods: A literature survey was conducted to identify patients with heterozygous CaSR mutations and NHPT. The common NHPT CaSR mutants R185Q and R227L were compared with 15 mutants causing only FHH in the heterozygous state. We studied in vitro calcium signaling including the functional consequences of co-expression of mutant and wild-type (wt) CaSR, patients' phenotype, age of disease manifestation and mode of inheritance. Results: All inactivating CaSR mutants impaired calcium signaling of wt-CaSR regardless of the patients' clinical phenotype. The absolute intracellular calcium signaling response to physiologic extracellular calcium concentrations in vitro showed a high correlation with patients' serum calcium concentrations in vivo, which is similar in NHPT and FHH patients with the same genotype. Pedigrees of FHH families revealed that paternal inheritance per se does not necessarily lead to NHPT but may only cause FHH. Conclusions: There is a significant correlation between in vitro functional impairment of the CaSR at physiologic calcium concentrations and the severity of alterations in calcium homeostasis in patients. Whether a particular genotype leads to NHPT or FHH appears to depend on additional predisposing genetic or environmental factors. An individual therapeutic approach appears to be warranted for NHPT patients.
Introduction
The calcium-sensing receptor (CaSR) is the key sensor for extracellular calcium (1, 2, 3) . It is expressed mainly in parathyroid tissue, kidney and bone and regulates parathyroid hormone (PTH) secretion and calcium handling in the kidney. The CaSR belongs to class C of the G protein-coupled receptor superfamily and activates the phospholipase C -calcium and other signaling pathways (4) .
Inactivating mutations of CaSR elevate the set point of receptor activation by extracellular calcium ([Ca give rise to hypercalcemic disorders such as neonatal severe hyperparathyroidism (NSHPT) caused by homozygous inactivating mutations and the rather benign disease familial hypocalciuric hypercalcemia (FHH) in adults caused by heterozygous inactivating mutations (1, 2, 5) . However, this clear-cut genotype-phenotype correlation does not hold in several well-documented cases of neonatal hyperparathyroidism, where only one mutated CaSR allele was found (Table 1) . In these cases, hypercalcemia with serum calcium levels of around 3 mM was similar to adult patients with the same mutant but only FHH. In contrast, typical patients with neonatal severe hyperparathyroidism (NSHPT) have serum calcium concentrations between 5 and 8 mM (Table 1 and (5, 6, 7, 8) ). The milder form of neonatal hyperparathyroidism is therefore more appropriately called NHPT (neonatal hyperparathyroidism).
Although the total or near-total loss of CaSR function in homozygous patients readily explains the severe biochemical and clinical phenotype in NSHPT, it is unclear why heterozygous CaSR mutations in some cases lead to serious clinical problems shortly after birth (NHPT), whereas in majority of patients no or only minor symptoms exist in adults (FHH).
One explanation proposed is that in NHPT, the mutated CaSR protein has a negative effect on the wild-type (wt) CaSR transcribed from the remaining normal allele, which results in impaired CaSR signaling in cells expressing both mutant and wt-CaSR (1, 9 ). An alternative explanation attributed the NHPT phenotype to a paternally inherited or de novo CaSR mutant. This leads to the unique situation of a fetus with an impaired CaSR function developing in a maternal environment with a normal CaSR (9, 10) .
Neither hypothesis about the pathophysiology of NHPT has been comprehensively tested by studying functional impairment and negative effects of CaSR mutants on wt-CaSR in vitro, the mode of inheritance and the clinical phenotype in vivo.
Subjects and methods

Patients and mutants
A literature search was performed to identify CaSR mutants that can cause NHPT in the heterozygous state. We chose the mutants R185Q and R227L for further in vitro analyses because there are six documented cases of NHPT with a heterozygous R185Q mutation and the amino acid R227 offered the possibility to study an NHPT mutant (R227L) Table 1) . For additional comparison, we selected CaSR mutants from published reports and our own FHH patients where a complete history and biochemical workup was available to assess the clinical phenotype and its time of manifestation. Patients' family history and genetic studies were reviewed to determine the mode of inheritance of the CaSR mutation. This study was performed according to the Bavarian state law (Bayerisches Krankenhausgesetz/Bavarian Hospital Law Art. 27 paragraph 4) that allows the use of patient data for research, provided that any person's related data are kept anonymous. In addition, this study was also examined by a local ethics committee, and a written statement was provided verifying that no ethics committee review was required for this study and that there were no concerns regarding its publication.
Functional analyses of CaSR function
Expression plasmids for wt-CaSR and 17 mutants from patients with NSHPT, NHPT and FHH (Table 1) were generated by site-directed mutagenesis, confirmed by sequencing and expressed in HEK 293T cells cultured on glass coverslips as described before (11, 12, 13, 14) . One microgram CaSR expression vector or, for co-transfection experiments, 0.5 µg mutant CaSR and 0.5 µg YFP-tagged wt-CaSR were used for transient transfection. Transiently transfected HEK 293T cells were loaded with 5 µM Fura-2/AM (Invitrogen), placed in superfusion buffer and used for measurements of cytosolic free calcium ([Ca 2+ ] i ) by dual-wavelength excitation microfluorometry. Dose-response curves were carried out as described (11, 12, 13, 14) . Protein expression was analyzed by Western blotting (Supplementary Methods and Supplementary Fig. 1 , see section on supplementary data given at the end of this article).
Statistical analysis
Nonlinear regression of dose-response curves was performed with GraphPad Prism 6 (GraphPad) using ∆ ] i response and 95% confidence intervals were determined from the nonlinear regression curves (12, 14) . The regression fits of wt and mutant/wt-CaSR were tested for statistically significant differences with an F-test using GraphPad Prism 6 (GraphPad) by comparing two nested models as described (14) . In the first model, the parameters EC 50 or maximum ∆ [Ca 2+ ] i response were common for both wt and mutant CaSR, and in the second model, these parameters were allowed to be different.
Linear correlation analyses of average serum calcium levels in heterozygous patients without prior parathyroidectomy or cinacalcet or bisphosphonate therapy (taken from ] o from 0.5 to 30 mM at 0.1 mM intervals (derived from dose-response curves shown in Fig. 1 ). Results were confirmed using SigmaPlot version 11.0 (Systat, Erkrath, Germany).
Results
Mutant CaSR attenuates wt-CaSR-induced calcium signaling in vitro
The NSHPT mutant R227X showed no increase in [Ca 2+ ] i in response to stimulation with [Ca 2+ ] o as expected ( Supplementary Fig. 1, solid lines) . By contrast, the NHPT mutants R185Q and R227L showed less severe signaling impairment with marked shifts of EC 50 for extracellular calcium [Ca 2+ ] o to the right but no decrease in maximum [Ca 2+ ] i response ( Supplementary Fig. 1 , solid lines, and Table 2 ). All mutants from FHH patients showed an impaired signaling function with increases in EC 50 and/or a reduction of the maximal [Ca 2+ ] i response ( Table 2) . Co-expression of most CaSR mutants with wt-CaSR (Fig. 1, dashed ] i increase was clearly attenuated.
There was hardly any overlap of the 95% confidence intervals in cells co-expressing wt-CaSR and the R185Q CaSR mutant compared with cells expressing wt-CaSR only (Fig. 1, dashed lines co-expressed with the other NHPT mutant R227L. The FHH mutants R227G and R227Q also attenuated the wt-CaSR cytosolic calcium response at low extracellular calcium. By contrast, the truncated CaSR mutant R227X, which in the heterozygous state barely leads to a rise in serum calcium level in affected patients (Table 1) , did not seem to affect the wt-CaSR-induced cytosolic calcium response at [Ca 2+ ] o below 4 mM (Fig. 1, dashed ] o with a r value of −0.829 (P = 0.000022) (Fig. 2A) . This indicates a highly significant negative correlation of patients' in vivo serum calcium levels with the in vitro ability to activate cytosolic calcium signaling in response to [Ca 2+ ] o in the physiologic range. Accordingly, patients heterozygous for the R185Q CaSR mutation had high serum calcium levels, whereas patients heterozygous for R227X CaSR had only mildly elevated serum calcium levels (Fig. 2B) . Remarkably, there is no apparent difference between NHPT and non-NHPT mutants. This demonstrates a strong link between the functional impairment of the CaSR to activate the calcium signaling pathway in vitro and in vivo calcium homeostasis in patients regardless of clinical phenotype.
Paternal inheritance per se does not cause NHPT
There are reports about 14 patients with a heterozygous R185Q CaSR mutation, who had no neonatal symptoms (Table 1 ). This clearly demonstrates that additional factors exist, which determine the clinical phenotype and its time of manifestation. We reviewed our patient's family histories in order to assess the impact of paternal inheritance or de novo mutation (Table 1) . In two families, we identified a total of four subjects harboring heterozygous CaSR mutations, who were born to mothers with wt-CaSR (Fig. 3) . None of the four individuals (one with a L159F/wt and three with a C851F/wt genotype) had clinical symptoms as neonates. They presented as asymptomatic FHH with rather high serum calcium levels and were diagnosed between the age of 11 and 39 years because of family screening or routine blood tests. Both, the L159F and the C851F CaSR mutant, caused a similar impairment of the cytosolic calcium response at 2.0 mM [Ca 2+ ] o as the R185Q mutant when co-expressed with wt-CaSR (Fig. 2B ). This demonstrates that paternal inheritance per se does not necessarily lead to NHPT.
Discussion
Genotype, function and phenotype
NHPT patients with symptomatic hyperparathyroidism shortly after birth contradict the paradigm that heterozygous CaSR mutations cause rather mild or asymptomatic FHH phenotypes in adults and that a homozygous CaSR mutation is required for a neonatal phenotype. This apparent exception from the genotypephenotype relationship has been attributed to a dominantnegative effect of CaSR mutants causing NHPT on the wt-CaSR (1, 9). Consistently, the R185Q and R227L CaSR mutants impaired wt-CaSR-dependent cytosolic calcium signaling as described previously (9, 15 Table 1 and the midpoint of the reference range of serum calcium (Fig. 1) . The observed correlation at low [Ca 2+ ] o appears to explain most of the changes in the calcium metabolism in affected patients. Thus, a function-phenotype model appears to predict the clinical disturbances of the calcium homeostasis in NHPT and FHH patients better than a simple genotypephenotype model. The finding that the vast majority of inactivating CaSR mutants negatively affects wt-CaSR signaling function fits well into this concept. Loss of one CaSR allele leads to only mild FHH in mice (16) , and it has been noticed before that FHH patients with mutants that completely abolish protein expression from one allele tend to have lower serum calcium levels compared with FHH patients that express a functionally impaired CaSR protein (17) . This is also nicely illustrated by the in vitro and in vivo differences observed between truncation and point mutations occurring at the same amino acid. Patients with the CaSR truncation mutants R227X and R185X have lower serum calcium levels than those with R227G, Q, L or R185Q mutants (Table 1 and (18)). A dominant-negative impact of mutant CaSR has been previously suspected to underlie elevated serum calcium levels in FHH patients (15, 17) , and this notion is clearly supported by our results.
Homeostasis and clinical severity
In FHH and NSHPT, there is a good correlation between alterations in calcium metabolism and the overall clinical severity. FHH patients have moderately elevated serum calcium levels and are mostly asymptomatic, whereas homozygous NSHPT patients have grossly elevated serum calcium concentrations and are critically ill. In contrast, NHPT and FHH patients have very similar serum calcium levels, particularly those with the same heterozygous mutations. The mutant R185Q is by far the most frequent mutation in NHPT patients reported so far with six published cases. There are, however, four reports with a total of 14 patients harboring the same genotype but presenting as FHH (Table 1) . R185Q/wt patients with NHPT have serum calcium levels between 3.1 and 3.6 mM and R185Q/wt patients with FHH between 2.9 and 3.4 mM ( Table 1) . NHPT patients with heterozygous mutations in other amino acids have serum calcium levels between 2.8 and 3.2 mM, whereas typical homozygous NSHPT patients have serum calcium levels between 5 and 8 mM (Table 1 and (5, 6, 7, 8) ). In fetuses and neonates with heterozygous CaSR mutations, the alteration of calcium homeostasis and the overall severity of the clinical phenotype can obviously be dissociated. 
Inheritance
Paternal inheritance or a de novo CaSR mutation has been suggested as one possible explanation for the development of NHPT (9, 10) . In this and in previous studies, however, neonates with heterozygous CaSR mutations born to mothers with wt-CaSR did not develop NHPT (Fig. 3 and Table 1 ). Nevertheless, it is noteworthy that none of the published cases of heterozygous NHPT was born to a mother with a mutated CaSR (Table 1, (19, 20, 21, 22) ). Thus, paternal inheritance or a de novo CaSR mutation does not cause NHPT per se, but there may be genetic factors such as allelic imbalance that predispose or contribute to the risk for NHPT.
Calcium and vitamin D supply
Metabolic bone disease and osteopenia are a clinical hallmark of NHPT (Table 1 and (19, 20, 23) ). During fetal development, calcium is exclusively supplied by the mother via active placental transport that is stimulated by fetal PTH-related peptide (PTHrP) but not by maternal or fetal PTH (24) . PTHrP is highly expressed in murine fetal parathyroid glands and its secretion seems to be regulated through CaSR-dependent mechanism, as in CaSR knockout fetuses plasma PTHrP levels as well as placental calcium transport are reduced (25) . If in humans the same regulatory mechanisms exist, impaired CaSR activity would cause decreased PTHrP expression and reduced calcium supply to the fetus. The resulting fetal calcium deficiency can lead to secondary hyperparathyroidism, which is exaggerated by the elevated calcium set point due to the inactivating CaSR mutant. Both low calcium and high PTH promote clinically significant metabolic bone disease. A similar pathomechanism has been observed in a young FHH patient with rickets due to pronounced calcium and vitamin D deficiency (13) . In NHPT patients, vitamin D deficiency is common (Table 1 and (19, 20, 23) ), and as in FHH patients, sufficient calcium and vitamin D supply reduces PTH and improves metabolic bone disease (13, 20) . By contrast, calcium restriction can lead to a further rise in PTH and a lack of clinical improvement (26) . This model of calcium deficiency and an exaggerated secondary hyperparathyroidism explains quite well the observed pathologic changes in NHPT patients. Further support is provided by several cases, in which NHPT was self-limited under supportive care and normal nutrition despite stable (27) or even slightly rising (21, 28, 29) serum calcium levels. According to this concept, NHPT may develop if the combined effects of impairment of wt-CaSR function by the mutant and of additional environmental or genetic factors that reduce maternal calcium supply to the fetus reach a critical threshold. This could also explain the variable phenotype in patients heterozygous for the R185Q CaSR mutant, but direct effects of the mutant CaSR on chondrocytes and osteoblasts may also contribute to the phenotype.
Summary
Taken together, there is a strong and highly significant correlation between functional impairment of CaSRdependent calcium signaling and patients' serum calcium levels. Patients with complete or near-complete loss of CaSR signaling, for example, due to severely inactivating homozygous CaSR mutations develop NSHPT with excessive PTH secretion that is not suppressed by even grossly elevated serum calcium levels. In contrast, patients with only mild impairment of CaSR function develop FHH. CaSR mutants that cause a more pronounced inhibition of wt-CaSR at physiological calcium concentrations may either lead to a neonatal phenotype (NHPT) or to FHH. Additional environmental and/or genetic factors such as allelic imbalance that critically reduce maternal-fetal calcium transfer may determine whether a particular genotype leads to NHPT instead of FHH. Calcium deficiency during fetal development combined with an exaggerated secondary hyperparathyroidism due to impaired overall CaSR function may then lead to neonatal manifestation as NHPT with serious metabolic bone disease, possibly also in patients with mutations that until now have only led to FHH. Although homozygous NSHPT and heterozygous NHPT have similarities in clinical phenotype, heterozygous NHPT shares pathophysiologic characteristics with FHH. An individual therapeutic approach to NHPT patients appears warranted.
